Dana-Farber, Philips data-driven precision oncology platform goes live

Listen
Text
  • Small
  • Medium
  • Large

Oncology Pathways, a platform developed by Philips and integrating Boston-based Dana-Farber Cancer Institute's Clinical Pathways decision-making tool, is now live, just over a year after the two organizations announced their partnership.

Dana-Farber's Clinical Pathways tool analyzes clinical data and oncologist insights to offer physicians recommendations for care management of cancer patients. The new solution integrates that tool into Philips' IntelliSpace Oncology platform, which processes radiology, pathology, genomics and EHR data to develop precision treatments.

When combined into the newly launched Oncology Pathways platform, the two solutions give providers access to both an advanced analytics platform and the expertise of more than 300 of Dana-Farber's oncologists, scientists, pharmacists, data scientists and informatics experts to select the most effective cancer treatments for each patient.

"The pathways platform is easily accessible in the midst of a busy clinical practice, guides physicians to the recommended treatment in a visually intuitive way, provides one-click access to supporting literature and creates a regimen-specific consent form," said Joseph Jacobson, MD, Dana-Farber's chief quality officer. "Of equal importance, the platform facilitates the selection of off-pathway choices when the on-pathway recommendation is not the best option for the patient."

More articles on health IT:
Health tech leaders release privacy guidelines for consumer health data
AHA report: 3 shifts providers must make to embrace digital health
St. Luke's University Health Network aims to provide a frictionless patient experience — technology can get them there

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars